Overcoming Challenges with Poorly Soluble Molecules in Early Development
By Emilie Bergström
Integrated Development Strategies, Part 2: Reformulating for clinical and commercial success
By Dr. Andy Lewis
How to balance time, costs and development risk when choosing the appropriate dosage form for your first-in-human Phase I trials?
By Dr. Peter Scholes
Candidate selection & API characterization: How do we assess the right molecules to take forward into development?